Welcome to our dedicated page for ACCUSTEM SCIENCES news (Ticker: ACUT), a resource for investors and traders seeking the latest updates and insights on ACCUSTEM SCIENCES stock.
AccuStem Sciences Inc. develops clinical-stage cancer diagnostics centered on proprietary molecular testing for screening, treatment planning, and monitoring. Its news commonly covers the MSC test, a non-invasive blood-based MicroRNA Signature Classifier that analyzes 24 circulating microRNAs to classify lung nodules by malignancy risk in lung cancer screening workflows.
Company updates also include StemPrintER studies in breast cancer, collaborations with diagnostic and clinical research organizations, blood-sample access agreements, testing infrastructure for microRNA extraction, investor presentations, and board-level share purchase announcements. These developments reflect AccuStem’s focus on cancer biology, including tumor stemness, and on translating molecular assays into clinical diagnostic use.
AccuStem Sciences (OTCQB: ACUT) announces plans to launch its microRNA Signature Classifier (MSC) blood test for lung cancer screening in the US. The test will initially target 1.6 million patients diagnosed yearly with nodules, with potential expansion to 15 million at-risk patients qualifying for annual screening.
The MSC test, developed at Istituto Nazionale Tumori, has been evaluated in over 5,000 patients across multiple clinical trials. When combined with low dose computed tomography (LDCT), MSC reduced false positive rates from 19.4% to 3.7%. The BioMILD trial showed MSC+ patients are four times more likely to have or develop lung cancer compared to MSC- patients.
AccuStem aims to commercialize the test in the US in 2026, potentially reducing unnecessary lung biopsies and healthcare costs. The company sees this as a significant opportunity to improve care outcomes for patients with lung nodules and plans to expand its use as a pre-screening tool before LDCT.
AccuStem Sciences (OTCQB: ACUT) has acquired the license for the proprietary microRNA Signature Classifier (MSC) test, a blood-based lung cancer screening technology. The test, developed by researchers at Istituto Nazionale Tumori (INT), evaluates 24 micro RNAs to enhance the accuracy of low-dose computed tomography (LDCT) in patients with pulmonary nodules.
Published data demonstrates that patients who test positive for both MSC and LDCT have a 30-fold higher cumulative lung cancer incidence compared to those negative for both tests. The combination of MSC with LDCT shows a five-fold reduction in false positives versus LDCT alone, potentially leading to improved outcomes and reduced healthcare costs.
The acquisition terms include issuing 3,750,000 common shares of AccuStem, with a 13-month resale restriction period. The company plans to launch the MSC test in the US in 2026.
AccuStem Sciences (OTCQB: ACUT), a clinical stage diagnostics company focused on cancer patient outcomes, has announced that its Board Chairman, Gabriele Cerrone, has acquired an additional 100,000 ACUT shares through open market purchases. Following this transaction, Cerrone's total shareholding has increased to 4,719,957 shares.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
AccuStem Sciences (OTCQB: ACUT) announced that its Chairman, Gabriele Cerrone, has acquired an additional 24,500 shares, bringing his total ownership to 3,855,723 shares. This purchase reflects the Chairman's confidence in the company’s future, as AccuStem focuses on developing innovative molecular testing for cancer diagnostics aimed at improving patient outcomes. The company is dedicated to addressing critical clinical needs throughout cancer screening, treatment, and monitoring.